Pathology update to the Manchester Scoring System based on testing in over 4000 families.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620405
Title:
Pathology update to the Manchester Scoring System based on testing in over 4000 families.
Authors:
Evans, D Gareth R; Harkness, E; Plaskocinska, I; Wallace, A; Clancy, T; Woodward, E; Howell, Anthony ( 0000-0002-3879-5991 ) ; Tischkowitz, M; Lalloo, F
Abstract:
While the requirement for thresholds for testing for mutations in BRCA1/2 is being questioned, they are likely to remain for individuals unaffected by a relevant cancer. It is still useful to provide pretesting likelihoods, but models need to take into account tumour pathology.
Affiliation:
Prevent Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe, Manchester, UK
Citation:
Pathology update to the Manchester Scoring System based on testing in over 4000 families. 2017 J Med Genet
Journal:
Journal of Medical Genetics
Issue Date:
10-May-2017
URI:
http://hdl.handle.net/10541/620405
DOI:
10.1136/jmedgenet-2017-104584
PubMed ID:
28490612
Type:
Article
Language:
en
ISSN:
1468-6244
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEvans, D Gareth Ren
dc.contributor.authorHarkness, Een
dc.contributor.authorPlaskocinska, Ien
dc.contributor.authorWallace, Aen
dc.contributor.authorClancy, Ten
dc.contributor.authorWoodward, Een
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorTischkowitz, Men
dc.contributor.authorLalloo, Fen
dc.date.accessioned2017-06-29T10:16:27Z-
dc.date.available2017-06-29T10:16:27Z-
dc.date.issued2017-05-10-
dc.identifier.citationPathology update to the Manchester Scoring System based on testing in over 4000 families. 2017 J Med Geneten
dc.identifier.issn1468-6244-
dc.identifier.pmid28490612-
dc.identifier.doi10.1136/jmedgenet-2017-104584-
dc.identifier.urihttp://hdl.handle.net/10541/620405-
dc.description.abstractWhile the requirement for thresholds for testing for mutations in BRCA1/2 is being questioned, they are likely to remain for individuals unaffected by a relevant cancer. It is still useful to provide pretesting likelihoods, but models need to take into account tumour pathology.en
dc.language.isoenen
dc.rightsArchived with thanks to Journal of medical geneticsen
dc.titlePathology update to the Manchester Scoring System based on testing in over 4000 families.en
dc.typeArticleen
dc.contributor.departmentPrevent Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe, Manchester, UKen
dc.identifier.journalJournal of Medical Geneticsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.